Life Science Nation Newsletter  |  July 17, 2014  |  Issue 71

In This Issue
Mapping Out the Early Stage Fundraising Dilemma  
RESI Announces Venture Philanthropy Panel 


Shaking the Tree: Experimenting with Outreach Methods to Get Investor Meetings

Life Science Investor Mandates (Jul. 9 - Jul. 15)
Seeking Life Science Investments Globally

Looking Opportunistically for Life Science Investments

Seeking Investments for Multiple Funds

LSN Videos
[Book] The Life Science Executive's Fundraising Manifesto
Recent News
in collaboration with the UMASS Boston VDC

"Reinventing Investment"
"Beyond Venture Capital"
Quick Links

Mapping Out the Early Stage Fundraising Dilemma
By Dennis Ford, Founder & CEO, LSN

After decades of government, nonprofit, and private funding of translational scientific research, there is a glut of early stage life science companies with great deal of promising data ready to go on to the next stage of preclinical and clinical development. However, many of these life science start-ups lack the capital to take the next steps toward commercialization for three main reasons.


Developing Relationships with New Categories of Life Science Investors Is a Challenge


The migration of VC dollars to later-stage investments has disoriented early stage fundraising executives, even though a new group of investors has surfaced to fill the early stage life science investment void. How to identify and market to these new investors remains a conundrum for fundraising executives. There is no easy solution to match up the thousands of early stage life science companies looking for capital with the thousands of early stage life science investors who have capital to invest...

Passion Meets Investment; Patients Win: RESI Conference Announces Venture Philanthropy Panel
By Tom Crosby, RESI Conference Manager, LSN

At LSN's next RESI Conference, the Venture Philanthropy Panel will bring together five leaders at top venture philanthropy organizations from around the U.S. to discuss their experience with impact investing-currently one of the most talked about funding models for early stage life science investments. Typically funding on a multiyear basis, these heavily donor-funded organizations are forging a path for significant results on a quick timeline.


Moderated by Brian Horsburgh, Trustee at the NeuroNetworks Fund, the audience will hear from:

  • Charlotte Hubbert, Venture Investor, Bill & Melinda Gates Foundation
  • Tim Armour, President & CEO, Cure Alzheimer's Fund
  • Albert Roy, CEO, Lupus Therapeutics
  • Daniel Auclair, VP of Translational Research, Multiple Myeloma Research Fund
Shaking the Tree: Experimenting with Outreach Methods to Get Investor Meetings
By Lucy Parkinson, Research Manager, LSN


Scientists pursue many different approaches when doing lab research. However, when it comes to fundraising, they often repeat the same actions and expect different outcomes-which has been said to be the definition of insanity.


If your process for connecting with investors isn't working, don't continue to do what you've been doing. Try something different. At LSN, we use an approach we call "shaking the tree." We find that by continuing to approach investors using various tactics, some fruit usually falls.


Some investors are easy to connect with; perhaps we happen to catch them at the right time, or the first thing we say happens to catch their interest. But success on a first attempt is more a matter of luck; gathering LSN's comprehensive intelligence on life science investors requires a systematic approach...

Address: 9B Hamilton Place, Boston, MA, 02108, USA

Phone: +1 (617) 600-0668

Email: [email protected]

follow us: Follow us on Twitter View our profile on LinkedIn